B
CR-ABL kinase domain (KD) point mutations are detected in the dominant tumor clone(s) in approximately 45% of patients with chronic myeloid leukemia (CML) at the time of disease resistance and develop after an average of 20 to 35 months of imatinib (Gleevec) therapy. [1] [2] [3] Second-and third-generation kinase inhibitors (KIs), including dasatinib, 4 nilotinib, 5 bosutinib, 6 INNO-406, 6 and MK-0457, 7 are used currently for imatinib-resistant CML, and each is associated with a somewhat different spectrum of KD mutations most likely related to the differing sensitivity of mutant clones to these agents. 8, 9 The algorithms for monitoring after imatinib resistance in CML are becoming well established. 10, 11 The clinical scenario in which BCR-ABL KD mutations are detected in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) is less clear but has been associated mostly with recurrent disease after treatment with chemotherapy followed by maintenance therapy with tyrosine KIs (TKIs). 12 Because current therapy for Ph-positive ALL includes chemotherapy combined with imatinib therapy, [13] [14] [15] [16] the timing of emergence and the overall pattern of BCR-ABL KD mutations are highly relevant. Furthermore, the differences between the biology of lymphoid blast crisis versus de novo Ph-positive ALL remains unclear. 17 To determine the pattern of KD mutation in Ph-positive ALL, we assessed the patterns of BCR-ABL KD mutations at diagnosis, at the time of disease recurrence, and after salvage therapy with second KIs.
MATERIALS AND METHODS

Patient Population
Patients with Ph-positive ALL who were seen at our institution over the previous 5 years and who had adequate available RNA from an involved sample (>10% blasts) were analyzed. All but 2 patients were adults aged >19 years. Diagnostic criteria were those of the World Health Organization International Histological Classification of Tumors. 18 All but 2 patients had B-cell lineage ALL, which was determined by an extensive flow-cytometric antigen panel; the remaining 2 patients had myeloid/B-cell biphenotypic lineage ALL. Patients who presented with CML in lymphoid blast crisis were excluded. Therapy for Phpositive ALL in most patients was hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) chemotherapy alternating with high-dose cytosine arabinoside and methotrexate along with imatinib at a dose from 400 to 800 mg/day either with/without vincristine or 6-mercaptopurine and methotrexate with/without vincristine and steroids (POMP) as maintenance (individual treatments are summarized in Table 1 ). 13 Patients who presented outside of our institution were treated initially with a variety of intensive multiagent chemotherapy regimens with 400 to 800 mg/ day of imatinib. Twelve patients with recurrent, Phpositive ALL who had received hyper-CVAD (with or without rituximab) but no imatinib therapy also were studied for comparison. Therapy for recurrent disease was variable and included dasatinib (with or without additional chemotherapy) in 9 patients, 4, 5 other TKIs in 4 patients, and MK-0457 in 3 patients. 7 Eight patients underwent stem cell transplantation in first or second remission. 19 For monitoring of treatment response, BCR-ABL polymerase chain reaction (PCR) studies were done every 1 to 3 months on peripheral blood during the induction phase. Standard cytogenetic analysis of Giemsa (G)-banded metaphases was done on bone marrow aspirates, and fluorescence in situ hybridization (FISH) studies using BCR-ABL fusion probes were done along with the PCR studies on blood every 3 months to 6 months during the maintenance phase and during remission and at recurrence.
RNA Isolation and Quantitative BCR-ABL PCR
White blood cells from bone marrow aspirates or peripheral blood specimens were isolated by centrifugation after erythrocyte lysis. Total RNA was extracted using Trizol reagent (Gibco-BRL, Gaithersburg, Md), and RNA quality was assessed by agarose gel electrophoresis before complementary DNA synthesis. Real-time quantitative PCR for BCR-ABL was performed in a 1-tube reaction with normalization to total ABL levels and post-PCR sizing of fusion transcript products done as described previously.
20,21
KD Mutation Detection
To avoid interference from the normal ABL allele, a nested PCR sequencing approach was used with a first-round amplification of the BCR-ABL transcript followed by 2 separate PCR reactions that covered codons 221 through 380 and codons 350 through 500 of the ABL KD. 22 Standard dideoxy chain-termination DNA sequencing was performed using Big Dye chain terminator reagents on an ABI3700 analyzer and was analyzed using Sequence Analysis software V3.3 and the SeqScape software V2 (ABI, Foster City, Calif). 1 All mutations were confirmed by sequencing of forward and reverse strands with a sensitivity of 10% mutation-bearing transcripts in the analyzed population. The mutation level for direct sequencing is reported semiquantitatively in Table 1 as only mutant (100%), mostly mutant (75%), mixed (50%), or mostly unmutated (25%).
For mutation analysis of codons 311-317 and codons 250-255, pyrosequencing was performed after first-round PCR as described above and with different second-round PCR reactions. Second-round PCR was performed using a biotin-tagged primer and single-stranded product isolated with avidin-sepharose beads (GE Life Sciences, Piscataway, NJ) and was sequenced using an HSQ96 Pyrosequencer (Biotage, Uppsala, Sweden). The sensitivity of pyrosequencing was approximately 1% to 5% mutation-bearing transcripts in the total BCR-ABL transcript pool. The mutation level for pyrosequencing is reported in Table 1 as the percent mutated product, with an established precision of 5% for the assay. By using a nested PCR-based assay to directly sequence the entire ABL KD of the BCR-ABL fusion transcript, no KD mutations were noted at recurrence in the 12 patients with Ph-positive ALL who had received no prior KI therapy. The frequency and pattern of BCR-ABL KD mutation development among the 24 patients who had received KI therapy before recurrence are summarized in Table 1 . BCR-ABL KD mutations were noted by direct sequencing in 15 of 17 patients (88%) who had morphologic evidence of recurrence after only imatinib therapy (n 5 16 patients) or dasatinib therapy (n 5 1 patient). The sites of KD mutation were Y253H in 6 patients (c. (Fig. 1) . All mutations were detected in peripheral blood or bone marrow aspirate samples, although concurrent recurrence in the central nervous system commonly was noted. The median time from diagnosis to mutation detection was 10 months (range, 6-24 months) with mutations in codons 253 and 315 developing most frequently in patients who had received continuous KI therapy in the preceding months compared with patients who had some breaks in imatinib maintenance therapy. The 2 patients on imatinib maintenance who developed recurrent disease without detectable KD mutations also had received intermittent KI therapy.
BCR-ABL KD mutations also were noted in 6 of 7 patients (86%) who presented at our institution with recurrent/persistent Ph-positive ALL after having received 2 or more KIs. The sites of KD mutation were T315I in 4 patients (c.1308C?T); Y253H (c.1121T?C), F317L (c.1315C?A), and E355G (c.1428A?G) in 1 patient each who received dasatinib after imatinib; and Y253H (c.1121T?C) in 1 patient who received nilotinib after imatinib. One patient who had previously received imatinib, nilotinib, and dasatinib (in that order) had 3 KD mutations, including T315I, F317L, and E355G, and all were present at mixed levels, suggesting 3 distinct clones. The median duration of KI therapy at the time mutations were detected was 10 months, and the median time on second KI therapy was 4 months.
The median follow-up among the cohort of 24 KI-treated patients who developed disease recurrence was 29 months (range, 11-95 months), and 17 of 24 patients had died of disease at last follow-up (overall survival: range, 12-95 months). Table 2 summarizes the cytogenetic findings by conventional G-banded karyotype among the 24 patients with KI-treated recurrent tumors. Only 2 patients had t(9;22) as the sole abnormality at diagnosis, with extra copies of the Ph chromosome as indicated by derivative (der) chromosome 22 or more complex derivative ''marker'' (mar) chromosomes observed in 8 patients (all Ph 1 amplifications were confirmed by BCR-ABL fusion FISH studies). In patients who had complex karyotypes, there usually was re-emergence of a similar or related clone at the time of recurrence; however, 6 patients at first or second recurrence had clonal progression or emergence 46,XY,t(1;4)(q22;p15.3), del(2)(p14),add(2)(q37),add(7) (q36),der(9)add(9) (p24)t(9;22)(q34;q11.2), 110,add(11)(p14),214, del(14)(q21), add(18)(q22),der(22)t(9;22) (continued) of a (sub)clone that apparently was distinct from that observed at diagnosis. Table 1 also summarizes the outcome of patients with KD mutations who switched from one KI to another. Complete regression of one mutation and emergence of another was observed in 3 patients (Patients 1, 7, and 15), such as the complete shift from E355Q to F317L (c.1315C?A) at 5 months after a switch from imatinib to dasatinib. By using quantitative pyrosequencing, we noted that persistence and the level of particular mutations usually paralleled their predicted sensitivity to particular KIs from in vitro studies, 8, [23] [24] [25] 
Shifts in KD Mutation Can Occur After Switch to a Different KI
BCL-ABL KD Mutations Are Not Detectable at Diagnosis in Ph-positive ALL
To assess whether significant levels of BCR-ABL transcripts with KD mutations were present before KI use, we studied the diagnostic samples from 12 patients who ultimately developed a mutation at recurrence and did not detect any KD mutations. By using a more sensitive quantitative pyrosequencing assay, we also did not any detect mutations in Y253H, T315I, or F317L in these samples or in the initial diagnostic samples from 25 additional patients with of Ph-positive ALL who did not develop disease recurrence (not shown). KD mutations also were rare (2 of 12 patients) in persistent ALL during the first months of treatment; and, in those patients, mutations were not observed at the mutational hotspots seen at recurrence (Table 3 ).
DISCUSSION
We note that BCR-ABL KD mutation in Ph-positive ALL occurs predominantly in the setting of recurrence after KI maintenance therapy and involves a restricted subset of mutations that are among the most resistant in vitro to imatinib and most of the newer KIs, namely, T315I and Y253H (Figure 2 ). 26 Mutations were not observed at recurrence in those patients who did not receive KI as part of their treatments.
The higher incidence, rapid emergence, and restricted group of KD mutations observed in this study among patients who had recurrent, Ph-positive ALL, compared with patients who had KI-resistant CML, 11, 22, 27 is similar to another series recently reported, 28 but our results differ in some respects. By comparing KD mutations present at low levels at the time of diagnosis, Pfeifer et al. concluded that acquired therapy resistance in Ph-positive ALL is caused in part by mutated BCR-ABL clones that exist before KI therapy. 28 Those authors concluded that their finding supported the use of KIs as initial therapy to eradicate these pre-existing KD-mutated populations. Given the absence of a substantial population of any given KD-mutated clone detectable before mutation growth, our results favor selection after the initiation of KI therapy as the primary determinant of mutation emergence. In fact, many of the patients who developed KD mutations at recurrence were on continuous KI therapy from the time of diagnosis. The rapidity of KD mutation shifts that we observed in some patients after the introduction of a different KI (median, 4 months) also supports rapid KD mutation outgrowth in response to KIdriven selective pressure.
The selective pressure reflected in the high rate of KD mutation also provides strong evidence that BCR-ABL expression remains critical to the growth of Ph-positive ALL at recurrence. The more restricted sites of BCR-ABL mutations in Ph-positive ALL, compared with KI-resistant CML, may be related to the need for more active BCR-ABL kinase for growth/ transformation of lymphoid cells versus myeloid cells. This hypothesis also would be consistent with the frequent presence in Ph-positive ALL of BCR-ABL gene amplification, as evidenced by extra Ph chromosomes and the frequent finding of higher BCR-ABL transcript levels. Effects caused by differences in the signaling pathways for the p190 versus p210 BCR-ABL protein after KI therapy in lymphoid versus biphenotypic versus myeloid stem cell populations KI indicates kinase inhibitor. *Direct sequencing refers to full ABL kinase domain (KD) Sanger sequencing performed after a nested polymerase chain reaction (see Materials and Methods). y Tested were the diagnostic or pre-KI-treated samples from 12 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1 ALL) who eventually developed recurrent disease with a KD mutation. { Tested were samples from patients who had residual Ph1 ALL in the first 6 months of treatment with chemotherapy and KI. Low levels of S438C (c.1674C>G) and Q252H (c.1120G>T) mutations were detected by direct sequencing in 1 sample each.
§ Tested were 12 samples of recurrent disease from patients with Ph1 ALL who received chemotherapy regimens with no KI. k Sixteen patients had received imatinib only, and 1 patient had received dasatinib only before the detection of a KD mutation. Ten of those patients were diagnosed at the authors' institution (see Table 1 ), and the remaining patients were referred for recurrent ALL that was treated elsewhere (see Table 1 ). accessed from the Research Collaboratory for Structural Bioinformatics Protein Data Bank) was rendered with Molecular Biology Toolkit Protein Workshop software. 34 One ABL chain is shown with imatinib in its binding pocket highlighted in purple; ABL codon 253 is labeled green, codon 315 is labeled red, codon 317 is labeled yellow, and codon 355 is labeled blue.
also cannot be excluded. Finally, differences in the entry, binding, and metabolism of KIs in different leukocyte populations may influence the selection of KD-mutated clones in ALL versus CML. KIs clearly have an important role in therapy for recurrent, Ph-positive ALL. In particular, it has been demonstrated that dasatinib is effective for imatinib-treated, resistant/recurrent, Ph-positive ALL. 29, 30 However, the high rate of KD mutation development at recurrence suggests that KI-selected mutations can promote disease progression and has implications for the timing and duration of induction and maintenance therapy with KIs in Phpositive ALL. 13 The current data suggest that sequential or combination therapy with both imatinib and dasatinib preferentially may select for tumor clones with mutations that mediate resistance to both agents. The most common mutation that develops in this setting, T315I, is cross-resistant to most KIs. Whether chemotherapeutic agents in maintenance regimens other than KIs play a role in mediating the outgrowth of mutated clones deserves further study. In that regard, strategies to alternate KIs with other therapies during the maintenance phase 31 or replacement of KIs with other cytostatic chemotherapies once mutations are detected to allow clonal regression may be strategies worth exploring to minimize the biologic selection of resistant disease.
